Company Description
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally.
The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old.
It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.
Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Joshua Disbrow |
Contact Details
Address: Denver Corporate Center III, Suite 920 Denver, Colorado 80237 United States | |
| Phone | (720) 437-6580 |
| Website | aytubio.com |
Stock Details
| Ticker Symbol | AYTU |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001385818 |
| CUSIP Number | 054754874 |
| ISIN Number | US0547548588 |
| Employer ID | 47-0883144 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua R. Disbrow | Chairman and Chief Executive Officer |
| Mark K. Oki CPA | Chief Financial Officer, Secretary and Treasurer |
| Jarrett T. Disbrow Ph.D. | Chief Business Officer |
| Greg Pyszczymuka | Chief Commercial Officer |
| Margaret Cabano | Vice President of Operations |
| Russ McMahen | Senior Vice President of Research and Development |
| Ryan J. Selhorn CPA | Executive Vice President of Finance and Business Optimization |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 15, 2024 | EFFECT | Notice of Effectiveness |
| Oct 11, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Oct 3, 2024 | UPLOAD | Filing |
| Oct 1, 2024 | 8-K | Current Report |
| Sep 26, 2024 | 8-K | Current Report |
| Sep 26, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 26, 2024 | 10-K | Annual Report |